| Segment Reporting Disclosure [Text Block] |
We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. We manage our business based on two primary types of drug products: (i) diagnostic substances, including Tc 99m tilmanocept and other diagnostic applications of our Manocept platform, and NAV4694, and (ii) therapeutic development programs, including therapeutic applications of our Manocept platform and all development programs undertaken by MT. The information in the following tables is derived directly from each reportable segment’s financial reporting.
T
hree Months Ended March 31, 2018
| | | | | | | | | | | | | | Tc99m tilmanocept royalty revenue | | $ | 795 | | | $ | — | | | $ | — | | | $ | 795 | | | Grant and other revenue | | | 232,436 | | | | 43,214 | | | | — | | | | 275,650 | | | Total revenue | | | 233,231 | | | | 43,214 | | | | — | | | | 276,445 | | | Cost of goods sold | | | 318 | | | | — | | | | — | | | | 318 | | | Research and development expenses | | | 785,011 | | | | 213,945 | | | | — | | | | 998,956 | | Selling, general and administrative expenses, excluding depreciation and amortization (1)
| | | — | | | | 8,607 | | | | 1,729,778 | | | | 1,738,385 | | Depreciation and amortization (2)
| | | — | | | | — | | | | 37,987 | | | | 37,987 | | | | | | (552,098 | ) | | | (179,338 | ) | | | (1,767,765 | ) | | | (2,499,201 | ) | | | | | — | | | | — | | | | (4,238,761 | ) | | | (4,238,761 | ) | | Net loss | | | (552,098 | ) | | | (179,338 | ) | | | (6,006,526 | ) | | | (6,737,962 | ) | | Total assets, net of depreciation and amortization: | | | | | | | | | | | | | | | | | | United States | | $ | 13,077,979 | | | $ | 27,228 | | | $ | 5,189,637 | | | $ | 18,294,844 | | | International | | | 26,055 | | | | — | | | | 1,328 | | | | 27,383 | | | Capital expenditures | | | — | | | | — | | | | — | | | | — | |
T
hree Months Ended March 31, 2017
| | | | | | | | | | | | | | Grant and other revenue | | $ | 571,362 | | | $ | 8,668 | | | $ | — | | | $ | 580,030 | | | Research and development expenses | | | 413,202 | | | | 292,072 | | | | — | | | | 705,274 | | Selling, general and administrative expenses, excluding depreciation and amortization (
1
)
| | | — | | | | 2,521 | | | | 2,943,123 | | | | 2,945,644 | | Depreciation and amortization (
2
)
| | | — | | | | — | | | | 76,790 | | | | 76,790 | | Income (loss) from operations (
3
)
| | | 158,160 | | | | (285,925 | ) | | | (3,019,913 | ) | | | (3,147,678 | ) | | Other expense | | | — | | | | — | | | | (1,171,109 | ) | | | (1,171,109 | ) | | Income tax (expense) benefit | | | (53,254 | ) | | | 96,273 | | | | 1,411,153 | | | | 1,454,172 | | | Net income (loss) from continuing operations | | | 104,906 | | | | (189,652 | ) | | | (2,779,869 | ) | | | (2,864,615 | ) | | Loss from discontinued operations, net of tax | | | (255,861 | ) | | | — | | | | — | | | | (255,861 | ) | | Gain on sale of discontinued operations, net of tax | | | 88,701,501 | | | | — | | | | — | | | | 88,701,501 | | | Net income (loss) | | | 88,550,546 | | | | (189,652 | ) | | | (2,779,869 | ) | | | 85,581,025 | | | Total assets, net of depreciation and amortization: | | | | | | | | | | | | | | | | | | United States | | $ | 9,692,007 | | | $ | 897 | | | $ | 23,116,511 | | | $ | 32,809,415 | | | International | | | 115,279 | | | | — | | | | 893 | | | | 116,172 | | | Capital expenditures | | | — | | | | — | | | | — | | | | — | | | | | General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT. | | | | Depreciation and amortization is reflected in selling, general and administrative expenses ( $37,987 and $76,790 for the three -month periods ended March
31, 2018 and 2017, and $9,745 was included in discontinued operations for the three -month period ended March 31, 2017).
| | | | Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT. | | | | Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments. |
|